Elanco Animal Health Incorporated Revenue from Contract with Customer, Including Assessed Tax
Elanco Animal Health Incorporated (ELAN) reported Revenue from Contract with Customer, Including Assessed Tax of $4.41 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2023-03-01
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for the quarter ending 2022-12-31 was $984.00M, a 11.51% decline year-over-year.
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for the quarter ending 2022-09-30 was $1.03B, a 9.28% decline year-over-year.
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for the quarter ending 2022-06-30 was $1.18B, a 8.06% decline year-over-year.
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for the quarter ending 2022-03-31 was $1.23B, a 1.37% decline year-over-year.
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for fiscal 2022 was $4.41B, a 7.41% decline from fiscal 2021.
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for fiscal 2021 was $4.76B, a 45.64% increase from fiscal 2020.
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for fiscal 2020 was $3.27B, a 6.51% increase from fiscal 2019.
- Elanco Animal Health Incorporated revenue from contract with customer, including assessed tax for fiscal 2019 was $3.07B, a 0.14% increase from fiscal 2018.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month | Revenue from Contract with Customer, Including Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $984.00M derived: 10-K 12 month − 3 quarters · filed 2023-03-01 | $2.01B derived: sum of 2 quarters · filed 2023-03-01 | $3.19B derived: sum of 3 quarters · filed 2023-03-01 | $4.41B 10-K · filed 2023-03-01 | |
| 2022-09-30 | $1.03B 10-K · filed 2023-03-01 | $2.20B derived: sum of 2 quarters · filed 2023-03-01 | $3.43B derived: sum of 3 quarters · filed 2023-03-01 | $4.54B derived: sum of 4 quarters · filed 2023-03-01 | |
| 2022-06-30 | $1.18B 10-K · filed 2023-03-01 | $2.40B derived: sum of 2 quarters · filed 2023-03-01 | $3.51B derived: sum of 3 quarters · filed 2023-03-01 | $4.64B derived: sum of 4 quarters · filed 2023-03-01 | |
| 2022-03-31 | $1.23B 10-K · filed 2023-03-01 | $2.34B derived: sum of 2 quarters · filed 2023-03-01 | $3.47B derived: sum of 3 quarters · filed 2023-03-01 | $4.75B derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-12-31 | $1.11B 10-K · filed 2023-03-01 | $2.24B derived: sum of 2 quarters · filed 2023-03-01 | $3.52B derived: sum of 3 quarters · filed 2023-03-01 | $4.76B 10-K · filed 2023-03-01 | $4.76B 10-K · filed 2022-02-28 |
| 2021-09-30 | $1.13B 10-K · filed 2023-03-01 | $2.41B derived: sum of 2 quarters · filed 2023-03-01 | $3.65B derived: sum of 3 quarters · filed 2023-03-01 | $4.79B derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $1.28B 10-K · filed 2023-03-01 | $2.52B derived: sum of 2 quarters · filed 2023-03-01 | $3.66B derived: sum of 3 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $1.24B 10-K · filed 2023-03-01 | $2.38B derived: sum of 2 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $1.14B 10-K · filed 2021-03-01 | $3.27B 10-K · filed 2023-03-01 | $3.27B 10-K · filed 2021-03-01 | ||
| 2019-12-31 | $787.00M 10-K · filed 2021-03-01 | $1.56B derived: sum of 2 quarters · filed 2021-03-01 | $2.34B derived: sum of 3 quarters · filed 2021-03-01 | $3.07B 10-K · filed 2022-02-28 | |
| 2019-09-30 | $771.30M 10-K · filed 2020-02-28 | $1.55B derived: sum of 2 quarters · filed 2020-02-28 | $2.28B derived: sum of 3 quarters · filed 2020-02-28 | $3.08B derived: sum of 4 quarters · filed 2020-02-28 | |
| 2019-06-30 | $781.60M 10-K · filed 2020-02-28 | $1.51B derived: sum of 2 quarters · filed 2020-02-28 | $2.31B derived: sum of 3 quarters · filed 2020-02-28 | $3.07B derived: sum of 4 quarters · filed 2020-02-28 | |
| 2019-03-31 | $731.10M 10-K · filed 2020-02-28 | $1.53B derived: sum of 2 quarters · filed 2020-02-28 | $2.29B derived: sum of 3 quarters · filed 2020-02-28 | $3.06B derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-12-31 | $799.30M 10-K · filed 2020-02-28 | $1.56B derived: sum of 2 quarters · filed 2020-02-28 | $2.33B derived: sum of 3 quarters · filed 2020-02-28 | $3.07B 10-K · filed 2021-03-01 | |
| 2018-09-30 | $761.10M 10-K · filed 2020-02-28 | $1.53B derived: sum of 2 quarters · filed 2020-02-28 | $2.27B 10-Q · filed 2018-11-08 | $3.02B derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-06-30 | $770.20M 10-K · filed 2020-02-28 | $1.51B derived: sum of 2 quarters · filed 2020-02-28 | $2.26B derived: sum of 3 quarters · filed 2020-02-28 | $2.96B derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-03-31 | $736.20M 10-K · filed 2020-02-28 | $1.49B derived: sum of 2 quarters · filed 2020-02-28 | $2.19B derived: sum of 3 quarters · filed 2020-02-28 | $2.92B derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $754.30M 10-K · filed 2019-02-20 | $1.45B derived: sum of 2 quarters · filed 2019-02-20 | $2.18B derived: sum of 3 quarters · filed 2019-02-20 | $2.89B 10-K · filed 2020-02-28 | |
| 2017-09-30 | $697.10M 10-K · filed 2019-02-20 | $1.43B derived: sum of 2 quarters · filed 2019-02-20 | $2.13B 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $732.80M 10-K · filed 2019-02-20 | $1.44B derived: sum of 2 quarters · filed 2019-02-20 | |||
| 2017-03-31 | $704.80M 10-K · filed 2019-02-20 | ||||
| 2016-12-31 | $2.91B 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |